Real-world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old.
Rui SatoMichihisa MoriguchiKenji IwaiSatoshi TsuchiyaYuya SekoAya TakahashiKazufumi KobayashiSadahisa OgasawaraShunji WatanabeNaoki MorimotoNaoya KatoYoshito ItohTakeshi AramakiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
Both sorafenib and lenvatinib were effective and feasible for elderly patients with HCC. In terms of discontinuation due to AEs and subsequent MTT, sorafenib might be more desirable for elderly patients with HCC over 80 years.